Covaxin proven safe for children of 2-18 years age group in phase III study: Bharat Biotech

In a phase II/III research, Bharat Biotech International Ltd#39;s COVID-19 vaccine Covaxin was found to be safe, well-tolerated, and highly immunogenic in children and adolescents aged 2 to 18 years.

from Moneycontrol Business News https://ift.tt/buAiJ1p